skip to Main Content

Download the IBT Bioservices Guide to In Vitro Antibacterial Testing

IBT Bioservices is a provider of research support for the discovery and development of vaccines and therapeutics. We offer a suite of in vitrtests and animal models to support proof-of-concept, product down-selection and to evaluate candidate compound efficacy.

In this document we share with you the molecular and cell-based in vitro antibacterial assays IBT Bioservices has to offer to evaluate target and drug activity at each phase of the R&D process.

If you have any questions or would like to share any feedback about this document, we encourage you to be in touch.

    Back To Top
    Search
    Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
    Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
    Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
    Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

    Alpha (UK) – B. 1.1.7 / 501Y.V1

    amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

    Beta (South Africa) – B.1.351

    amino acid mutations: K417N, E484K, N501Y, D614G, A701V

    Gamma (Brazil) – P.1

    amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

    Epsilon (Ca, USA) B.1.427

    amino acid mutations: L452R, D614G

    SARS-CoV-2 Parental Strain Wild Type (Wuhan)
    SARS-CoV-2 D614G Variant

    amino acid mutations: D614G

    Epsilon (Ca, USA) B.1.429

    amino acid mutations: S13I, W152C, L452R, D614G

    SARS-CoV-2 Delta Variant

    amino acid mutations: L452R, E484Q